TorontoStartsBook a call

Future Obesity Drugs

Silicon Scoop · March 24, 2025

Future Obesity Drugs: The Next Generation of Weight Loss Treatments Index Introduction The obesity epidemic continues to surge globally, driving an urgent demand for more effective weight loss therapies. While drugs like Ozempic, Wegovy, and Mounjaro have revolutionized treatment options today, the next generation of obesity medications—collectively known as Future Obesity Drugs—promise even greater efficacy, […]

With Craig Major and Jon Irwin

Open audio in your browser
Future Obesity Drugs
Home » Future Obesity Drugs

Estimated reading time: 8 minutes

Future Obesity Drugs: The Next Generation of Weight Loss Treatments

Index

Introduction

The obesity epidemic continues to surge globally, driving an urgent demand for more effective weight loss therapies. While drugs like Ozempic, Wegovy, and Mounjaro have revolutionized treatment options today, the next generation of obesity medications—collectively known as Future Obesity Drugs—promise even greater efficacy, improved safety profiles, and novel delivery methods. This comprehensive resource examines how upcoming treatments compare with current drugs, the innovations behind them, and what they mean for the future of obesity management.

Overview of Current Obesity Drugs

Today’s obesity treatments predominantly feature glucagon-like peptide-1 (GLP-1) receptor agonists.

  • Ozempic and Wegovy (semaglutide): Initially developed for type 2 diabetes, these injectables now deliver significant weight loss by enhancing satiety and reducing appetite.
  • Mounjaro (tirzepatide): A dual agonist that targets both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, offering robust weight reduction and additional benefits such as improved cardiovascular outcomes.

These drugs have set high benchmarks but come with challenges like injection frequency, side effects, and manufacturing constraints.

Next-Generation Treatments: What’s on the Horizon

Innovative drugs under development are set to transform obesity care:

  • Retatrutide (Eli Lilly): Dubbed the “triple-action” drug, it targets GLP-1, GIP, and glucagon receptors to potentially deliver weight loss comparable to bariatric surgery.
  • Orforglipron (Eli Lilly): An oral GLP-1 receptor agonist aimed at improving patient convenience and market scalability by replacing weekly injections with a daily pill.
  • VK2735 (Viking Therapeutics): Tested in both pill and injection forms, this dual agonist promises faster and significant weight loss.
  • CagriSema (Novo Nordisk): A combination of semaglutide and cagrilintide (an amylin receptor agonist) designed to enhance weight loss beyond current standards.
  • Amycretin (Novo Nordisk): With promising early trial data showing rapid weight loss percentages, it could challenge the efficacy of existing treatments.
  • HU6 (Rivus Pharmaceuticals): An innovative prodrug of 2,4-dinitrophenol (DNP) designed to safely reduce liver fat and overall body weight.
  • Maridebart Cafraglutide (Amgen): An investigational candidate offering a longer-lasting monthly injection with dual activity on GLP-1 and GIP receptors.

Each of these future drugs aims to address limitations of current treatments while opening new avenues for patient-specific therapy.

Innovations in Mechanism of Action

Next-generation obesity drugs employ advanced biochemical strategies:

  • Multi-hormone Targeting: By activating multiple receptors simultaneously (e.g., GLP-1, GIP, glucagon), these drugs aim for synergistic effects that boost weight loss while preserving lean mass.
  • Dual and Triple Agonism: Combining mechanisms (such as in retatrutide and CagriSema) can enhance metabolic control and improve cardiovascular outcomes.
  • Biased Agonism: Some candidates are designed to preferentially stimulate beneficial signaling pathways while minimizing side effects—a significant leap in receptor pharmacology.

These innovations represent a substantial evolution from the single-target approaches of current drugs.

Advancements in Drug Delivery: Oral vs. Injectable

Delivery methods play a crucial role in patient adherence and market penetration:

  • Injectable Therapies: While highly effective, weekly injections may deter some patients. Current therapies like Ozempic and Mounjaro require careful handling and have associated storage issues.
  • Oral Formulations: Drugs such as orforglipron, danuglipron, and aleniglipron are being developed as oral alternatives. Oral GLP-1s could offer easier administration and wider accessibility, especially in regions where refrigeration is limited. However, they must overcome challenges like ensuring bioavailability and managing gastrointestinal side effects.

The future of obesity treatments lies in offering a diversified delivery toolkit to suit varying patient needs.

Economic, Regulatory, and Market Trends

The obesity drug market is projected to expand dramatically:

  • Market Growth: Analysts predict the GLP-1 market could reach over $200 billion by the 2030s, driven by increasing patient demand and an untapped market of millions.
  • Supply Chain and Manufacturing: Despite robust demand, current manufacturing capacities are strained, prompting companies to invest in new production technologies and processes.
  • Regulatory Dynamics: Evolving regulatory frameworks are adapting to support innovative therapies, with some drugs already receiving breakthrough designations and priority reviews.
  • Investment Landscape: With companies like Novo Nordisk and Eli Lilly commanding high market valuations, investors remain keenly focused on pipeline developments and clinical trial outcomes.

Understanding these trends is crucial for stakeholders anticipating the next wave of obesity treatments.

The Role of AI and Automation in Obesity Drug Development

Artificial intelligence and automation are reshaping pharmaceutical research and development:

  • Streamlined Clinical Trials: AI-driven data analysis helps identify promising drug candidates faster and optimize trial design for better efficacy and safety outcomes.
  • Predictive Modeling: Advanced algorithms forecast long-term patient responses and potential side effects, reducing trial failures and accelerating time-to-market.
  • Manufacturing Optimization: Automation technologies improve drug synthesis and quality control, addressing supply chain bottlenecks and lowering production costs.
  • Personalized Medicine: AI tools enable the customization of treatments based on genetic, metabolic, and lifestyle factors, enhancing patient outcomes and adherence.

For companies looking to leverage these innovations, integrating AI into research workflows is a game changer.

Challenges and Considerations for Future Therapies

Despite exciting prospects, several hurdles remain:

  • Safety and Tolerability: As drugs become more potent, managing side effects such as gastrointestinal disturbances, potential cardiovascular risks, and long-term safety profiles is critical.
  • Cost and Accessibility: High drug prices and reimbursement challenges may limit access, especially in lower-income markets. Strategies to lower manufacturing costs and secure regulatory approvals are essential.
  • Patient Adherence: Even with oral options, strict dosing schedules and dietary restrictions could impact real-world effectiveness.
  • Long-Term Outcomes: While early data are promising, long-term studies are needed to evaluate durability of weight loss and overall health benefits.

Addressing these challenges will be key to the successful adoption of Future Obesity Drugs.

Conclusion & Call to Action

The pipeline for future obesity drugs is richer and more diverse than ever, promising groundbreaking improvements over current treatments. With innovative mechanisms of action, advanced delivery systems, and AI-enhanced research, these next-generation therapies could revolutionize obesity management and significantly reduce the burden of obesity-related diseases.

For companies ready to harness the power of AI and automation to transform their operations and accelerate innovation, visit flowgrammer.ca and book a discovery call today.

FAQ

Q1: What are Future Obesity Drugs?
Future Obesity Drugs refer to next-generation treatments that aim to provide improved weight loss, safety, and convenience compared to current medications like GLP-1 receptor agonists.
Learn more on Wikipedia: GLP-1 receptor agonist.

Q2: How do these new drugs differ from current treatments?
They often combine multiple hormonal actions, use innovative delivery methods (oral pills vs. injections), and leverage AI for optimized development.

Q3: Why is there a focus on oral formulations?
Oral drugs offer easier administration, potentially improve patient adherence, and address supply and storage challenges associated with injectables.

Q4: What role does AI play in developing these drugs?
AI streamlines clinical trial design, predicts patient outcomes, optimizes manufacturing processes, and personalizes treatment plans.

Q5: Are these future drugs safe?
Early clinical trials show promising efficacy and safety profiles, though long-term studies are essential to fully understand potential risks.

Q6: How will these drugs impact healthcare costs?
While initial costs may be high, increased competition and improved manufacturing could drive prices down, making them more accessible over time.

Q7: When will these drugs be available?
Many candidates are in Phase II or III trials, with some expected to hit the market within the next few years, pending regulatory approval.

Q8: What are the main challenges facing Future Obesity Drugs?
Key challenges include managing side effects, ensuring cost-effectiveness, improving patient adherence, and addressing supply chain constraints.

This article aims to provide an in-depth look at the emerging landscape of Future Obesity Drugs, comparing new therapies with current treatments and exploring their potential impact on healthcare. For further insights and to discuss how AI and automation can revolutionize your business processes, visit flowgrammer.ca and book a discovery call.

Additional Links
• Silicon Scoop Podcast – Stay Informed, Stay Ahead!
• Futuretech Podcast – Explore more episodes and stay updated with the latest in technology and innovation.
• Startup Talk Podcast – https://torontostarts.com/startup-talk-toronto-startup-podcast/
• Who Are These Startups Podcast
• Startup Investor Drinks – Join the community and connect with fellow startup enthusiasts and investors.
• TorontoStarts Startup and Entrepreneur Community – Become a part of Toronto’s thriving startup ecosystem.
• Workhaus – Discover flexible workspace solutions for your business needs.
• Work with The Startup Coach – Get expert guidance and mentorship for your startup journey.
• Reach out to Jon Irwin on LinkedIn – Connect with our co-host and technology expert.

Ontario Startup Ecosystem Links

• Ontario’s Startup Ecosystem
• Startup Funding in Ontario
• Angel Investors in Ontario
• Ontario Incubators and Accelerators
• Venture Capital in Ontario: Top Firms, Sectors, and Funding Strategies
• Government Grants for Ontario Startups
• Ontario’s Startup Success Stories
• Ontario Centre of Innovation (OCI)
• Bank Loans and Financing for Startups in Ontario
• Research and Development Tax Credits in Ontario
• Government Loans and Financing for Startups in Ontario
• Equity Crowdfunding for Ontario Startups
• Toronto Entrepreneurs Resources
• Toronto’s Food and Beverage Entrepreneurs: Trends, Challenges, and Success Stories
• SEO Strategies for Toronto Entrepreneurs: Enhance Your Online Visibility
• Social Impact for Toronto Entrepreneurs: Starting and Running a Socially Responsible Business
• Toronto Arts and Media Entrepreneurs: Inspiring Profiles and Insights for Creative Success
• Exploring Toronto Green Tech Entrepreneurs: Innovators and Leaders in Sustainability
• Building a Team for Toronto Entrepreneurs: Strategies for Success
• A Guide for Toronto Food and Beverage Entrepreneurs
• Toronto Fashion and Retail Entrepreneurs: Trends, Opportunities, and Success Stories

Episode transcript

Read the full transcript

Craig: here we have ozempic and wagolbe. wagolbe. yeah. wagolbe and mounjourno, but according to the articles we've been reading, the best is yet to come with obesity drugs. what's going on here, john?

Jon: yeah, well, here's the thing. so it's undergoing a revolutionary transformation with new generations of drugs showing crazy efficacy. so the thing is, the current and wegovy and ozempic, they're all what's called glp-one receptor antagonists. so the thing with these is that they were originally developed and used for diabetes treatment, specifically type two. so the first clinically approved glp-one receptor agonist was introduced in two thousand and five for the treatment of type two diabetes. since then they've realized, oh, well it treats diabetes, it helps with weight loss as well. so now because of this, so there's emerging treatments, particularly polyagonists that target multiple hormone receptors simultaneously, and they're showing a potential for greater weight loss and additional health benefits. so what they're doing is they're shifting, the development is shifting towards a more targeted approach with companies now designing medications specifically for obesity rather than repurposing diabetes treatments, which is cool. but, obviously, there's a long way to go. but what are your thoughts, craig?

Craig: i think i have mixed feelings about all of these things. only because i think there's some interesting side effects with the way these things do. they work. and there's a lot of people on them for extended period of times that probably shouldn't be. right. but they seem to work. like, it's they and people are using them for weight loss, but the stuff that's been out there is mostly for diabetic. so i'm curious to see how more effective these will be. like, i don't know if you went through all of these, but i, here are a few. i've no. both of them. good. okay. maybe i should've let you go through them because i'm horrible at the names here. retrotide dubbed the triple action drug at target targets glp-one, gip, and glucagon receptors to deliver potential weight loss comparable to bariatric surgery. o4 gilpran. yeah. sorry. ahead. yeah. how about you?

Jon: you don't have read the names. just go through

Craig: the i know. it's hilarious. yeah. but, let me zoom in here. there we go.

Jon: this is or glyphron?

Craig: yeah, there you go.

Jon: or for glyphron.

Craig: yeah. yeah. it's a oral glp-one receptor antagonist or agonist aimed to improving patient convenience and market scalability by replacing weekly injections with a pill. let me see. vk2735 from viking therapeutics tested both a pill and injection form. this is a dual agonist promises faster and efficient weight loss. cargi semma from novo nordisk. novo nordisk. yeah. a combination of semaglutide and carglenotide and hydro, avidylamin receptor agonist designed to enhance weight loss between current standards. amiacretin, with promising early trial data showing rapid weight loss percentages, it could challenge the efficacy of existing treatments. hu6 from rivas or rivas pharmaceuticals, an innovative prodrug of two point four ditropanol designed to safely reduce liver fat and overall body weight. and mari debart, kevragglutide, an investigational candidate offering a longer lasting monthly injection with dual activity on glp-one and gip receptors. so if anyone has any questions about why i didn't go into chemistry, just go back a few seconds and look at my pronunciations of these things. so there's a lot of cool stuff coming. some of the mechanisms include the multi hormone targeting, the dual and triple agonisms and the biased agonisms to really bump up the weight loss. and it's really nice that we're going to see oral versus injectable delivery.

Jon: yeah. and i think there is an oral glp-one that's out. can't remember who it's either eli lilly or novo nordisk that have released it but for those of you that don't know there's an actual naturally occurring glp-one in nature because you know me i'm trying to stay away from pharmaceuticals but cinnamon. cinnamon is a natural glp one. so there's other ones too, but that's the one that i put in my shakes now when i'm drinking. so the cool thing about this, what they're doing with these new, let's call them dual and triple agonists, is that they treat more than just obesity. so by focusing on obesity now, now you get other benefits for other things as opposed to treating for diabetes and it helps with obesity. so it could treat a lot of liver problems as well as glucose problems. like it could treat other things, but the thing is, and we, you kind of touched on it a little bit. i'm reading about these kind of horror stories about people using glp-one, some people losing their eyesight, some people losing bone density. it's crazy. it's risky using this stuff, which is why i'm more of the approach of, well, okay, what is naturally occurring and what can we use that's naturally occurring? maybe not as effective, but safer.

Craig: yeah. and what are the dosage levels and what are the cycles for going on something like this? because they get stomach paralysis and a bunch of other things that just sound, you know, horrible if you're on it for too long and doing different things or not necessarily following it properly. so, things need to be watched and managed and that's why i say people are on it for too long. maybe there's a six month cycle. maybe there's a thing where you go off and on. maybe. i don't know but to reduce the chances of these things or maybe these new drugs will have more of that covered as a result of what they're designed for.

Jon: yeah. exactly. yeah, and you hit it on the net, you hit the nail on the head too. like people are abusing these drugs too. so obviously there's going to be some problems and i know that there's also issues of too rapid of weight loss, so your skin can adjust. so then there comes other issues with loose skin and a whole bunch of different things. so yeah, i love that we're just scratching the surface of obesity drugs. i'm just worried about the side effects of these uses, right?

Craig: well, i, yes, and, you know, i'm worried about society as a whole, like, don't get me wrong, i'm not fit. i can use a bunch of lose weight and i work on it all the time. but i don't want to use these drugs. i want to do it. you know, my way. yeah. and that doesn't mean other people don't need help. other people don't want to use this. other people, i just, as a society, i don't want this to be the next thing. you know, you're just soon as your kid enters high school, he jumps on one of these weight loss drugs or whatever and everybody's on them for their life. this is what i'm worried about. so, other than that, i think it's a great option to have for people so that they can go from a debilitated state to a less debilitated one and get life back or feel healthy, feel good about their life, get less depressed, all the thousands of things that you need or want or whatever to give a life a quality of life. absolutely, i'm for that. but at the same time, you know, as a society, we become addicted to all these things. and i hope that there's some steps to prevent that from happening. yeah. so what do you think? are these drugs a godsend? and my concerns aren't concerns at all? and get out of the way, craig, let me at them or we should move cautiously into this new drug induced weight loss future? let us know what your thoughts are. leave your comments below.

More from Silicon Scoop

All episodes